依折麦布辛伐他汀(Ezetimibe/Simvastatin) - 药物靶点：HMG-CoA reductase x NPC1L1_在研适应症：冠状动脉疾病，家族性混合型高脂血症，II型高脂蛋白血症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Ezetimibe and Simvastatin、Inegy、Simvastatin/ezetimibe

+ [7]

靶点

HMG-CoA reductase x NPC1L1

作用机制

HMG-CoA reductase抑制剂(羟甲基戊二酰辅酶A合酶抑制剂)、NPC1L1抑制剂(尼曼-匹克C1型类似蛋白-1抑制剂)、胆固醇吸收抑制剂

治疗领域

神经系统疾病心血管疾病遗传病与畸形+ [2]

在研适应症

冠状动脉疾病家族性混合型高脂血症II型高脂蛋白血症+ [4]

非在研适应症

急性冠状动脉综合征主动脉瓣狭窄颈动脉疾病+ [5]

原研机构

Merck & Co., Inc.

在研机构

Organon & Co.MSD Technology Singapore Pte Ltd.

Merck & Co., Inc.

非在研机构

Merck Sharp & Dohme Corp.Schering-Plough Corp.

最高研发阶段批准上市

首次获批日期

瑞士 (1990-06-25),

高胆固醇血症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C49H59F2NO8

InChIKeyPNAMDJVUJCJOIX-IUNFJCKHSA-N

CAS号444313-53-5

关联

71

项与依折麦布辛伐他汀相关的临床试验

NCT06437574 / Recruiting临床2期IIT

Lowering Cholesterol in Prostate Cancer to Target Rapamycin-Insensitive Companion of MTOR (TORC2) in T-Cell Surface Glycoprotein CD8 Alpha Chain (CD8+) Lymphocytes

To test the hypothesis that intensive cholesterol lowering (iCL) therapy has anti-tumor immune modulating activity, the investigators will conduct an open-label, single-arm phase II trial in prostate cancer patients who are in active surveillance and undergoing a planned surveillance biopsy in 3-6 months. Eligible patients will initiate iCL with Vytorin®(group 1, 2, and 3), an FDA-approved combination of ezetimibe and simvastatin used to lower atherogenic low density lipoprotein cholesterol (LDL-C) or Ezetimibe (group 4). Starting dose will be determined by current statin use and LDL-C levels. Dose modifications of VYTORIN will be employed with the goal of achieving LDL-C <70 mg/dl. Dose adjustment is not allowed for ezetimibe.

开始日期2024-07-16

申办/合作机构

Cedars-Sinai Health System

CTR20241471 / CompletedN/A

依折麦布辛伐他汀片在中国成年健康受试者中的一项随机、开放、单次给药、两制剂、空腹四周期重复交叉、餐后三周期部分重复交叉的生物等效性研究。

考察空腹和餐后条件下单次口服受试制剂依折麦布辛伐他汀片T（规格：每片含依折麦布10 mg，辛伐他汀20 mg，江苏永安制药有限公司生产）与参比制剂依折麦布辛伐他汀片R（Ezetimibe and Simvastatin Tablets；商品名：葆至能®，规格：每片含依折麦布10 mg，辛伐他汀20 mg，MSD INTERNATIONAL GMBH （SINGAPORE BRANCH）生产）在健康人体内的吸收速度及吸收程度，评估空腹和餐后状态下分别口服两种制剂的人体生物等效性。

开始日期2024-05-11

申办/合作机构

安徽佳和药业有限公司初创企业

CTR20234033 / CompletedN/A

依折麦布辛伐他汀片在中国成年健康受试者中的一项随机、开放、单次给药、两制剂、空腹四周期重复交叉、餐后三周期部分重复交叉的生物等效性研究

主要研究目的：考察空腹和餐后条件下单次口服受试制剂依折麦布辛伐他汀片T（规格：每片含依折麦布10 mg，辛伐他汀20 mg，北京百奥药业有限责任公司生产）与参比制剂依折麦布辛伐他汀片R（Ezetimibe and Simvastatin Tablets；商品名：葆至能®，规格：每片含依折麦布10 mg，辛伐他汀20 mg，MSD INTERNATIONAL GMBH （SINGAPORE BRANCH）生产）在健康人体内的吸收速度及吸收程度，评估空腹和餐后状态下分别口服两种制剂的人体生物等效性。次要研究目的：评价受试制剂和参比制剂空腹和餐后条件下单次口服依折麦布辛伐他汀片在中国成年健康受试者中的安全性。

开始日期2023-12-14

申办/合作机构

北京百奥药业有限责任公司

100 项与依折麦布辛伐他汀相关的临床结果

登录后查看更多信息

100 项与依折麦布辛伐他汀相关的转化医学

登录后查看更多信息

100 项与依折麦布辛伐他汀相关的专利（医药）

登录后查看更多信息

109

项与依折麦布辛伐他汀相关的文献（医药）

2023-03-01·Current Atherosclerosis Reports

Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial

Review

作者: Oliver, Walter ; Giugliano, Robert P

PURPOSE OF REVIEWThe Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) demonstrated the clinical benefit of the combination of ezetimibe-simvastatin compared to placebo-simvastatin following acute coronary syndrome (ACS). This review highlights key findings from this study with particular attention to the practice-changing impact on guidelines for low-density lipoprotein cholesterol (LDL-C) reduction after ACS, especially among high-risk populations.RECENT FINDINGSConsistent reductions in LDL-C have been reported with newer lipid-lowering therapies (proprotein convertase subtilisin/kexin type 9 inhibitors, cholesterol ester transfer proteins, bempedoic acid) in combination with statin in high-risk subgroups. Since high-risk subgroups remain a focus of guidelines, exploration of high-risk subgroups can help define the optimal use of new therapies. Ezetimibe reduced the LDL-C by 16.7 mg/dL compared to placebo at 1 year, resulting in a significant reduction in the primary composite endpoint (absolute risk difference 2.0%; relative risk difference 6.4%, hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). The benefits achieved with ezetimibe in both LDL-C reduction and the primary clinical composite across 10 pre-specified high-risk subgroups, including the elderly; women; patients with diabetes, prior coronary artery bypass graft, history of stroke, polyvascular disease, low baseline LDL-C, renal dysfunction, prior heart failure, and an elevated TIMI risk score for secondary prevention, were similar or greater than in the corresponding non-high-risk subgroups. Safety events were similar between ezetimibe and placebo across the high-risk subgroups. These data support the addition of ezetimibe to statin therapy in high-risk patients who require additional therapy to lower the LDL-C post-ACS.

2022-12-01·JAMA Cardiology

Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome

Article

作者: Braunwald, Eugene ; Patel, Siddharth M. ; Marston, Nicholas A. ; Giugliano, Robert P. ; Blazing, Michael A. ; Qamar, Arman ; Jarolim, Petr ; Morrow, David A. ; Park, Jeong-Gun ; Cannon, Christopher P.

ImportanceStudies have demonstrated an association between single measures of high-sensitivity troponin (hsTn) and future cardiovascular events in patients with chronic coronary syndromes. However, limited data exist regarding the association between changes in serial values of hsTn and subsequent cardiovascular events in this patient population.ObjectiveTo evaluate the association between changes in high-sensitivity troponin T (hsTnT) and subsequent cardiovascular events in patients stabilized after acute coronary syndrome (ACS).Design, Setting, and ParticipantsThis is a secondary analysis from the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), a randomized clinical trial of ezetimibe vs placebo on a background of simvastatin in 18 144 patients hospitalized for an ACS across 1147 sites in 39 countries. The current biomarker substudy includes the 6035 participants consenting to the biomarker substudy with available hsTnT at months 1 and 4. Data were collected from October 26, 2005, through July 8, 2010, with the database locked October 21, 2014. Data were analyzed from February 28, 2021, through August 14, 2022.Main Outcomes and MeasuresThe outcomes of interest were cardiovascular death, myocardial infarction (MI), stroke, or hospitalization for heart failure (HHF). Associations of absolute and relative changes in hsTnT between month 1 and month 4 as a function of the starting month 1 hsTnT and the composite outcome were examined using landmark analyses.ResultsOf 6035 patients in this analysis (median [IQR] age, 64 [57-71]), 1486 (24.6%) were female; 361 (6.0%) were Asian; 121 were (2.0%) Black; 252 (4.2%) were Spanish descent; 4959 were (82.2%) White; and 342 (5.7%) reported another race (consolidated owing to small numbers), declined to respond, or were not asked to report race owing to regulatory prohibitions. Most patients (4114 [68.2%]) had stable hsTnT values (change &lt;3 ng/L), with 1158 (19.2%) and 763 (12.6%) having changes of 3 to less than 7 ng/L and 7 ng/L or more, respectively. After adjustment for clinical risk factors and stratification by the starting month 1 hsTnT level, an absolute increase in hsTnT of 7 ng/L or more was associated with a more than 3-fold greater risk of the composite outcome (adjusted hazard ratio [aHR], 3.33; 95% CI, 1.99-5.57; P &lt; .001), whereas decreases of 7 ng/L or more were associated with similar to lower risk (aHR, 0.51; 95% CI, 0.26-1.03; P = .06) compared with stable values. There was a stepwise association moving from larger absolute decreases (aHR, 0.51; 95% CI, 0.26-1.03) to larger absolute increases (aHR, 3.33; 95% CI, 1.99-5.57) in hsTnT with future risk of the composite outcome (P trend &lt;.001). A similar association was observed when analyzed on the basis of relative percent and continuous change.Conclusions and RelevanceAmong stable patients post-ACS, changes in hsTnT were associated with a gradient of risk of subsequent cardiovascular events across the range of starting hsTnT values. Serial assessment of hsTnT may refine risk stratification with the potential to guide therapy decisions in this patient population.Trial RegistrationClinicalTrials.gov Identifier: NCT00202878

2022-02-15·Journal of the American Heart Association2区 · 医学

Cardiovascular Events and Long‐Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE‐IT

2区 · 医学

ArticleOA

作者: Blazing, Michael A. ; Page, Courtney ; Giugliano, Robert P. ; Braunwald, Eugene ; Sharma, Abhinav ; Fordyce, Christopher B. ; Cannon, Christopher P. ; Lokhnygina, Yuliya ; Roe, Matthew T. ; White, Jennifer A.

BackgroundUnlike patients with low ejection fraction after an acute coronary syndrome (ACS), little is known about the long‐term incidence and influence of cardiovascular events before sudden death among stabilized patients after ACS.Methods and ResultsA total of 18 144 patients stabilized within 10 days after ACS in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) were studied. Cumulative incidence rates (IRs) and IRs per 100 patient‐years of sudden death were calculated. Using Cox proportional hazards, the association of ≥1 additional postrandomization cardiovascular events (myocardial infarction, stroke, and hospitalization for unstable angina or heart failure) with sudden death was examined. Early (≤1 year after ACS) and late sudden deaths (>1 year) were compared. Of 2446 total deaths, 402 (16%) were sudden. The median time to sudden death was 2.7 years, with 109 early and 293 late sudden deaths. The cumulative IR was 2.47% (95% CI, 2.23%–2.73%) at 7 years of follow‐up. The risk of sudden death following a postrandomization cardiovascular event (150/402 [37%] sudden deaths; median 1.4 years) was greater (IR/100 patient‐years, 1.45 [95% CI, 1.23–1.69]) than the risk with no postrandomization cardiovascular event (IR/100 patient‐years, 0.27 [95% CI, 0.24–0.30]). Postrandomization myocardial infarction (hazard ratio [HR], 3.64 [95% CI, 2.85–4.66]) and heart failure (HR, 4.55 [95% CI, 3.33–6.22]) significantly increased future risk of sudden death.ConclusionsPatients stabilized within 10 days of an ACS remain at long‐term risk of sudden death with the greatest risk in those with an additional cardiovascular event. These results refine the long‐term risk and risk effectors of sudden death, which may help clinicians identify opportunities to improve care. Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00202878.

35

项与依折麦布辛伐他汀相关的新闻（医药）

2024-09-29

·米内网

【瞩目】北京药企发威，同日拿下两大畅销产品

精彩内容 9月27日，福元医药发布公告称，拿下了两个重磅新品。美沙拉秦肠溶片是肠道抗炎药物TOP1产品，普伐他汀钠片是HMGCoA还原酶抑制剂TOP3产品。今年以来，北京福元医药已有17个新品获批。表1：福元医药最新获批的产品来源：公司公告美沙拉秦肠溶片用于溃疡性结肠炎的治疗，包括急性发作期的治疗和防止复发的维持治疗和用于克罗恩病急性发作期的治疗。米内网数据显示，目前该产品有6家企业获得批文（原研+国产）。图1：美沙拉秦肠溶片的销售情况（单位：万元）来源：米内网格局数据库在中国三大终端六大市场（统计范围见文末），美沙拉秦肠溶片是肠道抗炎药物TOP1产品，2022-2023年的销售额保持在8亿元以上。福元医药是该产品国产第四家获批企业，公告中提到该项目研发投入超过1300万元(未经审计)。普伐他汀钠片用于治疗高脂血症、家族性高胆固醇血症。米内网数据显示，目前该产品有7家药企（原研+国产）获得批文。图2：2023年HMGCoA还原酶抑制剂TOP5产品来源：米内网格局数据库在中国三大终端六大市场，普伐他汀钠片是HMGCoA还原酶抑制剂TOP3产品，2021-2023年的销售额保持在10亿元以上，福元医药是该产品国产第六家获批企业（不含原研地产化），公告中提到该项目研发投入超过700万元(未经审计)。表2：福元医药今年以来获批的新产品来源：米内网中国申报进度（MED）数据库今年以来，福元医药及子公司已有17个新产品获批，涉及5个大类（13个亚类），其中依折麦布辛伐他汀片、美阿沙坦钾片为国内首仿（不含原研地产化），多巴丝肼片是公司首款获批的抗帕金森氏病药。资料来源：公司公告、米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至9月28日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

2024-09-11

·药融云

2亿+抗贫血补铁剂，福元医药成功拿下！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 9月11日，北京福元医药发布公告，公司提交的琥珀酸亚铁片获批上市。琥珀酸亚铁片是抗贫血补铁剂畅销产品，福元医药于2023年4月10日获CDE受理，此次，福元医药顺利获批，是第5家拿下该品种的药企。截图来源：企业公告琥珀酸亚铁片由LABORATOIRE X.O公司研发，最早于1997年5月在法国批准上市，用于缺铁性贫血的预防和治疗。铁是人体的重要组成部分，是形成血红蛋白和生物组织氧化过程所必需的物质。缺铁时，红细胞合成血红蛋白量减少，致使红细胞体积变小，携氧能力下降，形成缺铁性贫血，口服本品可补充铁元素，纠正缺铁性贫血。据药融云数据库显示，琥珀酸亚铁片在2023年全国院内市场的销售额超2亿元。截图来源：药融云全国医院销售数据库目前，国内市场上的琥珀酸亚铁相关制剂有琥珀酸亚铁片、琥珀酸亚铁缓释片以及琥珀酸亚铁片颗粒，而已有企业过评的产品仅涉及琥珀酸亚铁片。截至目前，琥珀酸亚铁片有湖南九典制药、金陵药业、湖南华纳大药厂、成都奥邦药业、北京福元医药5家药企过评。此次，福元医药顺利获批，是第5家拿下该品种的药企。截图来源：药融云过评药品汇总数据库截至目前，福元医药（含子公司）有超50款品种过评。2024年至今，福元医药（含子公司）有琥珀酸亚铁片、丙戊酸钠缓释片(Ⅰ)、丙酸氟替卡松乳膏等15个品种过评，其中美阿沙坦钾片、依折麦布辛伐他汀片、替米沙坦氢氯噻嗪片等8个品种为首家过评。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，申请药融云企业版免费试用！

上市批准医药出海一致性评价

2024-08-28

·药融云

福元医药爆发！拿下“增速”惊人的降压药首仿，同日并斩获2亿+畅销品种……

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 8月27日，据NMPA公示，北京福元医药提交的美阿沙坦钾片获批生产并视同过评。同日北京福元医药还拿下了畅销的尼麦角林片这款心血管系统药物，据药融云数据库显示，尼麦角林片在2023年全国院内市场的销售额超2亿元。截图来源：NMPA官网大涨的沙坦药11家药企围攻，北京福元医药斩获首仿美阿沙坦钾是武田开发的血管紧张素受体拮抗剂（ARB），与其他沙坦类药物作用机制相同，通过阻止血管紧张素与血管上的受体结合，抑制“肾素-血管紧张素-醛固酮”系统（RAAS），从而发挥降压作用。2021年1月，武田药品的美阿沙坦钾片获批中国进口。2022年进入医保。近2年美阿沙坦钾片院内市场迅速放量，2022年销售额超35万元，2023年销售额超1400万，同比增长达4011.62%。截图来源：药融云全国医院销售数据库此前，国内只有原研企业武田制药1家拥有美阿沙坦钾片的生产批文。齐鲁制药、仁合益康集团等多家企业已经完成BE试验，并递交仿制申请。在仿制药布局方面，国内共有11家企业递交了美阿沙坦钾片的新4类报产申请。此次北京福元医药顺利获批，斩获首家过评+国内首仿。截图来源：药融云过评药品汇总数据库超700亿元心血管系统药物市场，福元医药持续加码尼麦角林片是一款畅销的脑血管治疗用药，主要用于改善脑梗塞后遗症引起的意欲低下和情感障碍，急性和慢性周围循环障碍，也适用于血管性痴呆，尤其在早期治疗时对认知、记忆等有改善，并能减轻疾病严重程度。据药融云数据库显示，在2023年全国院内市场，心血管系统药物（化学药或生物药）总销售额达到743.5亿元，其中尼麦角林片的销售额超过2亿元。截图来源：药融云全国医院销售数据库目前，国内有9家企业拥有尼麦角林片生产批文。在仿制药布局方面，有浙江华海药业、华益泰康药业、山东齐都药业等9家药企提交了仿制申请，均在审评审批中。一致性评价方面，尼麦角林片有北京福元医药、福安药业集团、山东方明药业集团等7家药企已过评或视同过评。截图来源：药融云过评药品汇总数据库目前，北京福元医药有15款心血管系统药物过评或视同过评，其中替米沙坦氢氯噻嗪片、美阿沙坦钾片、依折麦布辛伐他汀片、氯沙坦钾氢氯噻嗪片4个品种为首家过评。2024年至今，北京福元医药有13个品种过评或视同过评。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PD 联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，申请药融云企业版免费试用！

一致性评价

100 项与依折麦布辛伐他汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	依折麦布辛伐他汀	C10BA02	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
冠状动脉疾病	中国	MSD Technology Singapore Pte Ltd.	2009-04-15
家族性混合型高脂血症	中国	MSD Technology Singapore Pte Ltd.	2009-04-15
II型高脂蛋白血症	中国	MSD Technology Singapore Pte Ltd.	2009-04-15
脑卒中	中国	MSD Technology Singapore Pte Ltd.	2009-04-15
纯合子家族性高胆固醇血症	美国	Organon & Co.	2004-07-23
原发性高胆固醇血症	美国	Organon & Co.	2004-07-23
高胆固醇血症	瑞士	Organon & Co.	1990-06-25

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
代谢综合征	临床2期	-	Organon & Co.	2007-07-01
1型糖尿病	临床2期	美国	Merck Sharp & Dohme Corp.	2007-05-01
血脂障碍	临床2期	美国	Merck Sharp & Dohme Corp.	2007-05-01
急性冠状动脉综合征	临床2期	-	Organon & Co.	2005-10-17
心肌梗塞	临床2期	-	Organon & Co.	2005-10-17
2型糖尿病	临床2期	-	Organon & Co.	2005-05-01
颈动脉疾病	临床2期	-	Organon & Co.	2004-01-27
冠心病	临床2期	-	Organon & Co.	2004-01-27
原发性高胆固醇血症	临床2期	-	Organon & Co.	2002-09-01
主动脉瓣狭窄	临床2期	-	Organon & Co.	2001-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01420328 (CTgov)	N/A	炎症 \| 肥胖	20	Placebo (Placebo Arm)	鹹築網範夢簾範觸遞積(製鬱願鬱醖鏇遞餘蓋鏇) = 顧鏇壓糧築夢齋夢齋窪鹽鹹夢構積遞獵衊壓艱 (網齋襯襯糧膚壓選鑰選, 壓積憲齋顧選築醖築顧 ~ 觸觸製膚顧觸選鏇網壓) 更多	-	2024-04-17
				Vytorin (Vytorin Arm)	鹹築網範夢簾範觸遞積(製鬱願鬱醖鏇遞餘蓋鏇) = 簾餘獵築窪鏇壓衊窪廠鹽鹹夢構積遞獵衊壓艱 (網齋襯襯糧膚壓選鑰選, 膚網築憲鬱鹽鹹夢醖齋 ~ 製鑰壓齋蓋遞窪壓糧醖) 更多
NCT00988364 (Merck-123, CTgov)	临床4期	代谢综合征	30	ezetimibe (Ezetimibe)	膚鹹積繭壓獵鹽鹹醖簾(鹽鑰膚憲願繭選餘糧積) = 憲構艱獵憲夢壓醖糧鑰願夢鏇願憲範窪窪繭鏇 (鬱憲醖選鑰鹹窪鑰醖廠, 製鏇餘艱獵壓窪醖壓簾 ~ 壓廠選範蓋鏇願鑰網鏇) 更多	-	2023-11-30
				Simvastatin (Simvastatin)	膚鹹積繭壓獵鹽鹹醖簾(鹽鑰膚憲願繭選餘糧積) = 憲選鹽顧淵願襯構選築願夢鏇願憲範窪窪繭鏇 (鬱憲醖選鑰鹹窪鑰醖廠, 選鹹窪築遞簾壓艱醖齋 ~ 壓襯衊廠鏇繭膚窪壓積) 更多
NCT00202878 (P04103 \| IMPROVE-IT, Pubmed \| JAMA Cardiol)	临床3期	急性冠状动脉综合征	18,144	Simvastatin-Ezetimibe	淵製憲鑰鬱鹹膚襯顧艱(鏇鹽鏇襯憲鬱壓鏇衊淵) = 淵壓鑰鏇鏇憲築醖積齋鬱蓋製蓋鏇獵鏇顧蓋範 (蓋鹽艱餘觸構獵艱醖醖 )	积极	2019-09-01
				Simvastatin Monotherapy	淵製憲鑰鬱鹹膚襯顧艱(鏇鹽鏇襯憲鬱壓鏇衊淵) = 鏇齋蓋顧淵鏇壓遞鏇餘鬱蓋製蓋鏇獵鏇顧蓋範 (蓋鹽艱餘觸構獵艱醖醖 )
NCT00202878 (P04103 \| IMPROVE-IT, Pubmed \| J Am Coll Cardiol)	临床3期	急性冠状动脉综合征	18,144	Ezetimibe/Simvastatin	鹹願窪觸鏇鹽積簾鹽糧(夢繭窪衊糧願繭繭襯範): RR = 0.91 (95% CI, 0.85 ~ 0.97), P-Value = 0.007 更多	-	2016-02-02
				Placebo/Simvastatin
NCT00202878 (P04103 \| IMPROVE-IT, CTgov)	临床3期	急性冠状动脉综合征 \| 心肌梗塞 \| 高胆固醇血症	18,144	Placebo for simvastatin 40 mg+ezetimibe/simvastatin (Ezetimibe/Simvastatin)	遞淵膚憲鹹積蓋鹽積襯(構簾範製夢獵醖築廠衊) = 壓衊觸餘淵窪鏇憲憲襯製構壓壓繭鏇鹽壓鹹憲 (顧鬱鹽壓鏇製齋範獵網, 築鏇顧觸獵顧醖繭築糧 ~ 觸鏇製衊範醖鑰鏇鬱鬱) 更多	-	2015-09-30
				Placebo for simvastatin 40 mg+simvastatin (Simvastatin)	遞淵膚憲鹹積蓋鹽積襯(構簾範製夢獵醖築廠衊) = 築範憲鬱衊繭鹽膚顧鑰製構壓壓繭鏇鹽壓鹹憲 (顧鬱鹽壓鏇製齋範獵網, 衊選築廠鹽遞遞廠願顧 ~ 蓋餘鬱繭獵製鏇夢獵簾) 更多
NCT00819403 (CTgov)	临床4期	代谢综合征	15	simvastatin (Simvastatin)	齋鑰淵壓築壓鬱壓鏇願(製糧範襯鬱鹽襯範網壓) = 憲築遞窪獵製獵鏇顧願壓構艱醖襯衊夢獵鏇鬱 (築窪蓋憲獵製顧衊膚鬱, 構鬱繭鏇壓衊蓋憲鏇範 ~ 顧選簾遞鹹觸遞製廠壓) 更多	-	2014-12-18
				ezetimibe/simvastatin (Simvastatin/Ezetimibe)	齋鑰淵壓築壓鬱壓鏇願(製糧範襯鬱鹽襯範網壓) = 壓憲積鹽淵繭艱鹹衊顧壓構艱醖襯衊夢獵鏇鬱 (築窪蓋憲獵製顧衊膚鬱, 獵憲鑰鬱夢壓獵憲淵選 ~ 範遞選積壓顧願積壓獵) 更多
NCT00461630 (HPS2-THRIVE, CTgov)	临床3期	糖尿病 \| 冠状动脉疾病 \| 外周动脉疾病	25,673	Simvastatin+ezetimibe/simvastatin+ER niacin/laropiprant (ER Niacin/Laropiprant)	夢鏇淵製餘鑰餘願艱鑰(蓋觸遞壓鏇廠夢獵鏇醖) = 簾遞艱糧網憲鹹鏇範簾蓋築蓋鹽醖範醖選鏇網 (窪築鹽廠製觸糧觸製夢, 憲積築網艱艱鏇觸遞獵 ~ 顧夢憲簾壓繭選窪網遞) 更多	-	2014-01-28
				Simvastatin+ezetimibe/simvastatin (Placebo)	夢鏇淵製餘鑰餘願艱鑰(蓋觸遞壓鏇廠夢獵鏇醖) = 製蓋膚齋壓夢願鏇顧淵蓋築蓋鹽醖範醖選鏇網 (窪築鹽廠製觸糧觸製夢, 餘築鹹選蓋憲鏇齋顧鏇 ~ 範齋衊糧窪蓋獵構糧觸) 更多
NCT01185236 (Pubmed \| Am J Cardiovasc Drugs)	临床4期	2型糖尿病	132	Ezetimibe/Simvastatin 10/20 mg	(窪積糧鏇壓願壓窪廠遞) = 醖憲齋顧鬱觸鏇廠窪簾簾窪壓觸夢鹽鏇窪願醖 (窪遞構憲鬱繭鬱膚醖觸 ) 更多	-	2013-10-01
				Atorvastatin 20 mg	(窪積糧鏇壓願壓窪廠遞) = 遞窪鏇醖艱襯淵獵壓觸簾窪壓觸夢鹽鏇窪願醖 (窪遞構憲鬱繭鬱膚醖觸 ) 更多
NCT00474123 (Pubmed \| J Cardiovasc Pharmacol Ther)	N/A	稳定型心绞痛	68	Simvastatin 80 mg	餘襯觸鏇構顧繭壓淵壓(繭夢淵艱憲觸鏇願顧繭) = 獵範獵憲襯夢積選齋壓蓋積鬱襯襯鬱簾鹹網簾 (襯積膚醖蓋築鹽壓艱鹹 ) 更多	-	2013-09-01
				Ezetimibe 10 mg/Simvastatin 20 mg	餘襯觸鏇構顧繭壓淵壓(繭夢淵艱憲觸鏇願顧繭) = 範構簾襯鹹簾範構顧範蓋積鬱襯襯鬱簾鹹網簾 (襯積膚醖蓋築鹽壓艱鹹 ) 更多
NCT00738972 (CTgov)	临床3期	左心室肥大 \| 高血压	12	pravastatin+valsartan (Valsartan 80 mg + Paravastin 40 mg)	願簾鏇襯簾鬱遞獵鬱範(網鑰壓網憲簾構鑰廠醖) = 蓋糧餘膚鏇蓋鬱醖製遞遞蓋廠窪醖齋廠範廠觸 (範膚鏇顧觸範構衊獵廠, 鑰構鏇獵壓觸糧鏇膚衊 ~ 餘鑰鏇艱積艱顧夢壓蓋) 更多	-	2013-08-13
				simvastatin+valsartan (Valsartan 80 mg + Simvastatin 40 mg)	願簾鏇襯簾鬱遞獵鬱範(網鑰壓網憲簾構鑰廠醖) = 觸願鹽觸獵積願顧鏇艱遞蓋廠窪醖齋廠範廠觸 (範膚鏇顧觸範構衊獵廠, 範遞膚繭夢願簾構鏇膚 ~ 齋壓範齋壓衊膚觸鏇願) 更多